Search Result

Pathways Recommended:	Protein Tyrosine Kinase/RTK

Results for "

Tyrosine kinase-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (1) Btk (1) DYRK (1) Syk (1) Antibiotic (1) Apoptosis (1) Autophagy (3) Bcr-Abl (2) c-Fms (3) c-Kit (3) c-Met/HGFR (2) CaMK (1) CDK (1) Drug Metabolite (1) EGFR (2) FGFR (2) GSK-3 (1) HIF/HIF Prolyl-Hydroxylase (1) IGF-1R (1) Insulin Receptor (3) Isotope-Labeled Compounds (1) PDGFR (4) PKA (1) PKC (1) Raf (1) RET (1) ROS Kinase (1) Src (1) TAM Receptor (1) Trk Receptor (1) VEGFR (4)
By Research Areas:	Cancer (20) Cardiovascular Disease (1) Endocrinology (1) Infection (1) Inflammation/Immunology (2) Metabolic Disease (2)

By Targets:

Anaplastic lymphoma kinase (ALK) (1)

Btk (1)

DYRK (1)

Syk (1)

Antibiotic (1)

Apoptosis (1)

Autophagy (3)

Bcr-Abl (2)

c-Fms (3)

c-Kit (3)

c-Met/HGFR (2)

CaMK (1)

CDK (1)

Drug Metabolite (1)

EGFR (2)

FGFR (2)

GSK-3 (1)

HIF/HIF Prolyl-Hydroxylase (1)

IGF-1R (1)

Insulin Receptor (3)

Isotope-Labeled Compounds (1)

PDGFR (4)

PKA (1)

PKC (1)

Raf (1)

RET (1)

ROS Kinase (1)

Src (1)

TAM Receptor (1)

Trk Receptor (1)

VEGFR (4)

By Research Areas:

Cancer (20)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (2)

Metabolic Disease (2)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Tyrosine Hydroxylase Btk Syk DYRK Dan family Pyk2 AIM2 NEKs BRK FAK FLT3 Anaplastic lymphoma kinase (ALK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100315

XL 999 TyrosINe kINase-IN-1	VEGFR PDGFR FGFR	Cardiovascular Disease
Kinase Assay: Kinase Inhibition Assays Kinase activities of KDR and PDGFRα are measured as the percent of ATP consumed following the kinase reaction using luciferaseluciferin-coupled chemiluminescence. Kinase reactions are initiated by combining test compound (XL 999), ATP, kinases and substrates in a 20 mL volume using 384-well microtiter plates. For KDR, the final reaction mixture contained 3 mM ATP, 1.6 mM poly(Glu, Tyr) 4:1 and 1.5 nM KDR of residues D807-V1356 with an N-terminal GST tag. For PDGFRα, the final reaction mixture contained 2 mM ATP, 10 mM MBP and 14 nM PDGFRα of residues Q551-L1089 with an N-terminal GST tag. The reaction mixture is incubated at room temperature for 4 h (KDR) or 2 h PDGFRα before a 20 mL aliquot of Kinase Glo is added and luminescence signal is measured using a Victor2 plate reader. Total ATP consumption is limited below 50% .

HY-156619

Labuxtinib	c-Kit	Cancer
Labuxtinib is c-kit tyrosine kinase inhibitor .

HY-148228

ROS kinases-IN-1	ROS Kinase	Cancer
ROS kinases-IN-1 (pag 98) is a ROS tyrosine kinase inhibitor with IC₅₀ value of 1.22 μM. ROS kinases-IN-1 shows anti-tumor activity .

HY-10331S

Regorafenib-d3 BAY 73-4506-d₃	VEGFR Autophagy PDGFR Raf RET	Cancer
Regorafenib-d₃ is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor[1].

HY-147612

Tyrosine kinase-IN-4	c-Met/HGFR	Cancer
Tyrosine kinase-IN-4 (EXAMPLE 107) is a protein **tyrosine kinase** inhibitor .

HY-159840

Fanregratinib	FGFR	Cancer
Fanregratinib is a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor .

HY-149895

Syk-IN-7	Syk	Cancer
Syk-IN-7 (compound 17) is an inhibitor of spleen tyrosine kinase (SYK) .

HY-P2547

**Tyrosine Kinase Peptide 1**	Src	Others
Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay .

HY-101962

HNMPA	Insulin Receptor	Metabolic Disease
HNMPA is a membrane impermeable insulin receptor tyrosine kinase inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities

HY-W062695

(R)-Acalabrutinib (R)-ACP-196	Btk	Cancer
(R)-Acalabrutinib ((R)-ACP-196) is the enantiomer of Acalabrutinib (HY-17600). (R)-Acalabrutinib is an inhibitor for Bruton’s tyrosine kinase (BTK) .

HY-15656S

Ceritinib-d7 LDK378 d₇	Isotope-Labeled Compounds Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R	Endocrinology Cancer
Ceritinib-d₇ is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].

HY-103032

Multi-kinase inhibitor 1	PDGFR c-Kit Bcr-Abl	Cancer
Multi-kinase inhibitor 1 is a potent *multi-kinase* inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl .

HY-117718

AG957 TyrphostIN AG957; NSC 654705	Bcr-Abl	Cancer
AG957 (Tyrphostin AG957;NSC 654705) is a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity . AG957 is a bcr/abl kinase inhibitor with an IC₅₀ of 2.9 μM for p210 ^bcr/abl autokinase activity .

HY-135742

Lenvatinib N-oxide LenvatINib impurity 10	VEGFR	Cancer
Lenvatinib N-Oxide (Lenvatinib impurity 10) is the impurity of Lenvatinib (HY-10981). Lenvatinib (E7080) is an orally active, multi-targeted tyrosine kinase inhibitor .

HY-131669

Dasatinib metabolite M6 DasatINib carboxylic acid	Drug Metabolite	Others Cancer
Dasatinib metabolite M6 (Dasatinib carboxylic acid) is an oxidative metabolite of Dasatinib (HY-10181). Dasatinib is a potent and orally active dual Bcr-Abl and Src family tyrosine kinase inhibitor .

HY-P1776

[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153)	Insulin Receptor	Metabolic Disease
[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates .

HY-P10569

Biotin HER-2 substrate peptide	EGFR	Cancer
Biotin HER-2 substrate peptide is a substrate of Her4 and Her2/neu tyrosine kinase with a K_m value of 60 μm for Her2/neu kinase domain .

HY-N12041

Axl-IN-16	TAM Receptor HIF/HIF Prolyl-Hydroxylase	Cancer
Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression .

HY-125017

Bozitinib 1 Publications Verification PLB-1001; CBT-101; VebreltINib	c-Met/HGFR	Cancer
Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily .

HY-163490

PKMYT1-IN-1	Others	Cancer
PKMYT1-IN-1 (Compound 1) is an inhibitor for membrane-associated tyrosine and threonine kinase (PKMYT1), with an IC₅₀ of 8.8 nM. PKMYT1-IN-1 inhibits proliferation of tumor cell HCC1569 with IC₅₀ of 42 nM .

HY-12768

Sotuletinib Maximum Cited Publications 24 Publications Verification BLZ945	c-Fms	Cancer
Sotuletinib (BLZ945) is a potent, selective and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC₅₀ of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs .

HY-50895G

Gefitinib ZD1839	EGFR Autophagy Apoptosis	Cancer
Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor .

HY-12768A

Sotuletinib hydrochloride Maximum Cited Publications 24 Publications Verification BLZ945 hydrochloride	c-Fms	Cancer
Sotuletinib (BLZ945) hydrochloride is a potent, selective and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC₅₀ of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs .

HY-N12625

(R)-(+)-O-Demethylbuchenavianine	CDK DYRK GSK-3	Cancer
(R)-(+)-O-Demethylbuchenavianine is an inhibitor for Cyclin-dependent kinases (CDK). (R)-(+)-O-Demethylbuchenavianine inhibits CDK1, CDK5, glycogen synthase kinase-3 (GSK3), cdc2-like kinase (CLK1) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), with IC₅₀s of 1.1, 0.95, >10, >10 and >10 μM, respectively .

HY-N6732

K-252a 10+ Cited Publications SF2370; Antibiotic K 252a; Antibiotic SF 2370	PKC PKA CaMK Trk Receptor Autophagy Antibiotic	Infection Inflammation/Immunology
K-252a, a staurosporine analog, inhibits protein kinase, with IC₅₀ values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca ²⁺/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC₅₀ of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .

HY-10408

Ki20227 5 Publications Verification	c-Fms VEGFR c-Kit PDGFR	Inflammation/Immunology
Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC₅₀s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction .

Cat. No.	Product Name	Type

HY-50895G

Gefitinib (GMP) ZD1839 (GMP)	Fluorescent Dye
Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor .

Cat. No.	Product Name	Type

HY-50895G

Gefitinib (GMP) ZD1839 (GMP)	Biochemical Assay Reagents
Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor .

**Tyrosine Kinase Peptide 1**	Src	Others
Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay .

[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153)	Insulin Receptor	Metabolic Disease
[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates .

Biotin HER-2 substrate peptide	EGFR	Cancer
Biotin HER-2 substrate peptide is a substrate of Her4 and Her2/neu tyrosine kinase with a K_m value of 60 μm for Her2/neu kinase domain .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N12625

(R)-(+)-O-Demethylbuchenavianine	Structural Classification Alkaloids Flavonoids Flavones Other Alkaloids Buchenavia macrophylla Spruce ex Eichler Combretaceae Source classification Plants	CDK DYRK GSK-3
(R)-(+)-O-Demethylbuchenavianine is an inhibitor for Cyclin-dependent kinases (CDK). (R)-(+)-O-Demethylbuchenavianine inhibits CDK1, CDK5, glycogen synthase kinase-3 (GSK3), cdc2-like kinase (CLK1) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), with IC₅₀s of 1.1, 0.95, >10, >10 and >10 μM, respectively .

HY-N6732

K-252a 10+ Cited Publications SF2370; Antibiotic K 252a; Antibiotic SF 2370	Alkaloids Structural Classification Microorganisms Classification of Application Fields Source classification Inflammation/Immunology Disease Research Fields Indole Alkaloids	PKC PKA CaMK Trk Receptor Autophagy Antibiotic
K-252a, a staurosporine analog, inhibits protein kinase, with IC₅₀ values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca ²⁺/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC₅₀ of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .

HY-N12041

Axl-IN-16	Structural Classification Natural Products Microorganisms Source classification	TAM Receptor HIF/HIF Prolyl-Hydroxylase
Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression .

Cat. No.	Product Name	Chemical Structure

HY-10331S

Regorafenib-d3
Regorafenib-d₃ is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor[1].

HY-15656S

Ceritinib-d7
Ceritinib-d₇ is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Tyrosine kinase-IN-1

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products